Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + lenvatinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination therapy regimen consisting of the PD-1 inhibitor sintilimab, the multi-kinase inhibitor lenvatinib, and the albumin-bound chemotherapy agent nab-paclitaxel. This triplet combination is being investigated in clinical trials, notably by Zhejiang Cancer Hospital, as a first-line treatment for patients with recurrent or metastatic triple-negative breast cancer (TNBC). Sintilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses. Lenvatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), and other kinases to inhibit angiogenesis and tumor growth. Nab-paclitaxel is a nanoparticle formulation of paclitaxel that stabilizes microtubules, leading to cell cycle arrest and apoptosis. The combination aims to provide a multi-pronged attack on TNBC by combining immune checkpoint blockade, anti-angiogenesis, and cytotoxic chemotherapy.
- Brand names
- TyvytLenvimaAbraxane
- Other names
- sindilimab + lenvatinib + nab-paclitaxelsintilimab + lenvatinib + nab-paclitaxelsindilimab-Zhejiang Cancer Hospital-triple-negative breast cancer
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on sintilimab + lenvatinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + lenvatinib + nab-paclitaxel.